1419 related articles for article (PubMed ID: 32223444)
41. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
42. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
[TBL] [Abstract][Full Text] [Related]
43. A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.
Gumprecht J; Domek M; Lip GYH
Expert Opin Drug Saf; 2019 Dec; 18(12):1119-1125. PubMed ID: 31580164
[No Abstract] [Full Text] [Related]
44. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Granger CB; Lopes RD; Hanna M; Ansell J; Hylek EM; Alexander JH; Thomas L; Wang J; Bahit MC; Verheugt F; Lawrence J; Xavier D; Wallentin L
Am Heart J; 2015 Jan; 169(1):25-30. PubMed ID: 25497244
[TBL] [Abstract][Full Text] [Related]
45. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
46. Critical appraisal of the AUGUSTUS trial.
Gremmel T; Sulzgruber P; Niessner A
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):187-188. PubMed ID: 31265054
[No Abstract] [Full Text] [Related]
47. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
[TBL] [Abstract][Full Text] [Related]
48. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
[TBL] [Abstract][Full Text] [Related]
49. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
50. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
[TBL] [Abstract][Full Text] [Related]
51. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
Mavrakanas TA; Garlo K; Charytan DM
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
[TBL] [Abstract][Full Text] [Related]
52. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
53. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Lamberts M; Olesen JB; Ruwald MH; Hansen CM; Karasoy D; Kristensen SL; Køber L; Torp-Pedersen C; Gislason GH; Hansen ML
Circulation; 2012 Sep; 126(10):1185-93. PubMed ID: 22869839
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Alings M; De Caterina R; Eikelboom JW; Ezekowitz MD; Held C; Huber K; Hylek EM; Granger CB; Lopes RD; Vinereanu D; Siegbahn A; Wallentin L
JAMA Netw Open; 2020 Sep; 3(9):e2015943. PubMed ID: 32936298
[TBL] [Abstract][Full Text] [Related]
55. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Hoshi T; Sato A; Nogami A; Gosho M; Aonuma K;
J Cardiol; 2017 Apr; 69(4):648-651. PubMed ID: 27443596
[TBL] [Abstract][Full Text] [Related]
56. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
57. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
[TBL] [Abstract][Full Text] [Related]
59. Apixaban versus warfarin in patients with atrial fibrillation.
Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
[TBL] [Abstract][Full Text] [Related]
60. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
